At AACR, first‑in‑human KIR‑CAR T data show early activity in solid tumors and introduce a novel design aimed at limiting T ...
A detailed analysis of T-cell redirecting therapies in oncology, comparing the mechanisms of bispecific antibodies and CAR T ...
A single infusion of ciltacabtagene autoleucel (Carvykti) led to a 100% minimal residual disease (MRD)-negativity rate in ...
In desperation, the woman’s care team reached out to Müller, a hematologist-oncologist at the University Hospital of Erlangen, a roughly three-hour drive away by ambulance. In recent years, he and his ...
CAR, was shown to be safe, with increasing efficacy corresponding to higher doses of the investigational treatment in nine ...
Over the last decade, the cellular cancer immunotherapy known as CAR T-cell therapy has roared to the rescue of many blood cancer patients. The engineered immune cells revolutionized treatment of ...
Among the most promising tools of cancer therapy, engineered immune cells known as chimeric antigen-receptor (CAR) T cells have already transformed the treatment of blood cancers. Yet, despite their ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results